Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 11:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 2,689 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Normal saline solution Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers

Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPM

NCT02838745
View directory record Official record
Conditions
Mesothelioma
Interventions
Pemetrexed, Cisplatin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 28, 2026, 11:31 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years

NCT00952419
View directory record Official record
Conditions
Influenza, Swine-origin A/H1N1 Influenza
Interventions
Monovalent Subvirion A/H1N1 Influenza vaccine, Normal saline solution (placebo)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 9 Years
Enrollment
474 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
20
States / cities
Miami Beach, Florida • Marietta, Georgia • Woodstock, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 28, 2026, 11:31 AM EDT
Completed Phase 1Phase 2 Interventional

YSPSL for Prevention of Delayed Graft Function Part B

NCT00298168
View directory record Official record
Conditions
Kidney Diseases
Interventions
YSPSL, placebo
Drug
Lead sponsor
Y's Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2008 · Synced Oct 28, 2026, 11:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First in Human Study of ORT247 in Healthy Volunteers

NCT06769620
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
ORT247, Placebo
Drug
Lead sponsor
Orthogonal Neuroscience Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 28, 2026, 11:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study for Safety of ACHN-490

NCT00822978
View directory record Official record
Conditions
Healthy
Interventions
ACHN-490 Injection vs placebo
Drug
Lead sponsor
Achaogen, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Oct 28, 2026, 11:31 AM EDT
Terminated Phase 3 Interventional Results available

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

NCT02626455
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Copanlisib (BAY80-6946), Placebo, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Bendamustine, Prednisone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
10
States / cities
Chandler, Arizona • West Covina, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 28, 2026, 11:31 AM EDT
Completed Phase 4 Interventional Results available

OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder

NCT01945489
View directory record Official record
Conditions
Overactive Bladder
Interventions
onabotulinumtoxinA, Normal saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
40
States / cities
Huntsville, Alabama • Anchorage, Alaska • Laguna Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 28, 2026, 11:31 AM EDT
Completed Phase 1 Interventional Results available

A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011)

NCT05656040
View directory record Official record
Conditions
End-Stage Renal Disease, End-Stage Kidney Disease, Kidney Failure, Chronic
Interventions
MK-2060, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Edgewater, Florida • Miami, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 28, 2026, 11:31 AM EDT
Completed Phase 2 Interventional Results available

Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction

NCT00367991
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Recombinant human erythropoietin alfa (drug), Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Oct 28, 2026, 11:31 AM EDT
Active, not recruiting Phase 3 Interventional

Microfragmented Adipose Tissue Compared to Saline Injection for the Treatment of Knee Osteoarthritis

NCT06121882
View directory record Official record
Conditions
Knee Osteoarthritis, Osteo Arthritis Knee
Interventions
Microfragmented Adipose Tissue derived using the Lipogems® System, Saline Injection
Device · Drug
Lead sponsor
Lipogems International spa
Industry
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
16
States / cities
Phoenix, Arizona • Encinitas, California • La Mesa, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 28, 2026, 11:31 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)

NCT00786474
View directory record Official record
Conditions
Arterial Thromboembolic Events, Atrial Fibrillation
Interventions
Placebo, Dalteparin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
1,884 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Oct 28, 2026, 11:31 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

In Vivo Patient Preoperative Skin Prep Persistence

NCT02447497
View directory record Official record
Conditions
Bacterial Recovery of Skin Flora Post-Product Application
Interventions
3M CHG/IPA Surgical Skin Preparation - Abdominal Region, Normal Saline - Abdominal Region, 3M CHG/IPA Surgical Skin Preparation - Inguinal Region, Normal Saline - Inguinal Region
Drug · Other
Lead sponsor
Solventum US LLC
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Sterling, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 28, 2026, 11:31 AM EDT
Terminated Phase 2 Interventional

A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.

NCT01522196
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis
Interventions
Varespladib, Placebo (Normal Saline)
Drug · Other
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
5 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 28, 2026, 11:31 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Infrapatellar Nerve Block for Post-operative Knee Arthroscopy Pain Control

NCT01279447
View directory record Official record
Conditions
Internal Derangement of Knee
Interventions
0.25% Bupivacaine, Normal Saline
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Oct 28, 2026, 11:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy Volunteers

NCT03564158
View directory record Official record
Conditions
Healthy
Interventions
meropenem-vaborbactam, Placebo, Moxifloxacin
Drug
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Industry
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 28, 2026, 11:31 AM EDT
Terminated Not applicable Interventional Results available

Glycemic Effects of Morning Only, Evening Only or Twice Daily Insulin Glargine in Patients With Type 1 Diabetes

NCT00869414
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia
Interventions
Evening only administration of insulin glargine, Morning only administration of insulin glargine, split dose insulin glargine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2017 · Synced Oct 28, 2026, 11:31 AM EDT
Completed Phase 2Phase 3 Interventional

Treatment Protocol for Use of Anascorp™ in Patients With Scorpion Sting Envenomation

NCT00624078
View directory record Official record
Conditions
Scorpion Sting Envenomation
Interventions
Antivenin Centruroides (scorpion) F(ab)2 Anascorp™
Drug
Lead sponsor
Instituto Bioclon S.A. de C.V.
Industry
Eligibility
Not listed
Enrollment
1,426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
18
States / cities
Casa Grande, Arizona • Chandler, Arizona • Douglas, Arizona + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2011 · Synced Oct 28, 2026, 11:31 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age

NCT05992935
View directory record Official record
Conditions
Norovirus Acute Gastroenteritis
Interventions
mRNA-1403, mRNA-1405, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
14
States / cities
Long Beach, California • Longmont, Colorado • Hollywood, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 28, 2026, 11:31 AM EDT
Completed No phase listed Observational

Comparison of Epidural and TAP Block in Abdominal Surgery

NCT01848951
View directory record Official record
Conditions
Acute Pain, Surgery, Regional Anesthesia
Interventions
Epidural, TAP Block
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 28, 2026, 11:31 AM EDT
Completed Phase 4 Interventional

Efficacy of Hematoma Block on Postoperative Pain After Femoral Intramedullary Rodding: A Randomized Trial

NCT04860856
View directory record Official record
Conditions
Femur Fracture
Interventions
0.5% ropivacaine, Normal Saline
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 28, 2026, 11:31 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of SL-325 in Healthy Volunteers

NCT07158437
View directory record Official record
Conditions
Healthy Volunteers
Interventions
SL-325, Placebo (Normal Saline)
Biological · Other
Lead sponsor
Shattuck Labs, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 28, 2026, 11:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Plasma Gelsolin in Healthy Volunteers

NCT05789745
View directory record Official record
Conditions
Volunteers, Healthy
Interventions
Recombinant human plasma gelsolin, placebo
Drug · Other
Lead sponsor
BioAegis Therapeutics Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 28, 2026, 11:31 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Normal Breathing and Swallowing in Healthy Volunteers

NCT03122145
View directory record Official record
Conditions
Healthy
Interventions
Capsaicin, Videofluoroscopic swallow study
Drug · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 28, 2026, 11:31 AM EDT
Not listed Phase 1Phase 2 Interventional

Safety and Feasibility of Hypertonic Saline Solution After Aneurysmal Subarachnoid Hemorrhage:

NCT02432157
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Cerebral Vasospasm, Hyponatremia
Interventions
HTS 3%, Standard fluid management
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Oct 28, 2026, 11:31 AM EDT